Product Information

BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE is a generic product labeled by Quagen Pharmaceuticals LLC, priced at $1.3780 per EA under NDC 70752014110. Its NADAC has been published 89 times since Mar 12, 2025.

FDA first approved this application on Mar 12, 2024. Its Orange Book therapeutic-equivalence code is AA.

BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
$1.3780per EA
DEA Schedule CIII

Strength

325; 50; 40 mg/1; mg/1; mg/1

NDC

70752014110

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

11/18/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA216376

FDA Approved

3/12/2024

TE Code

AA

On Market Since

8/6/2022

Pharmacological Classes

Barbiturate
Barbiturates
Central Nervous System Stimulant
Central Nervous System Stimulation
Methylxanthine
Xanthines

Price Statistics

The NADAC for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE has been published 89 times since Mar 12, 2025, and over the history we have for it it has declined 44.2%. The table below summarizes its recorded NADAC range and movement.

Current price$1.3780 per EA
All-time high$2.7647 (Apr 16, 2025)
All-time low$1.3780 (Nov 18, 2026)
52-week high$2.2534
52-week low$1.3780
Median price$2.2150
Average price$2.1121
Largest weekly change-16.2% (Nov 18, 2026)
Weeks tracked89
Tracking sinceMar 12, 2025

Price History

1W

-16.2%

1M

-28.6%

3M

-31.4%

6M

-20.4%

1Y

-38.1%

3Y

N/A

5Y

N/A

All

-44.2%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the BUTALBITAL, ACETAMINOPHEN AND CAFFEINE market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE, manufactured by Quagen Pharmaceuticals LLC, is $1.3780 per EA (NDC 70752014110), effective Nov 18, 2026.

How has the price of BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE has declined 44.2%. It has been tracked across 89 weekly CMS publications since Mar 12, 2025.

What are the highest and lowest recorded NADAC prices for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE?

Since Mar 12, 2025, the NADAC for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE has ranged from a low of $1.3780 (Nov 18, 2026) to a high of $2.7647 (Apr 16, 2025), with a median of $2.2150 per EA.

Are there cheaper alternatives to BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE?

No other NADAC-published product currently shares the active ingredient and strength of BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE?

BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE (NDC 70752014110) is labeled by Quagen Pharmaceuticals LLC, and CMS classifies it as a generic product.